Cargando…
Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
Autores principales: | Marcec, Robert, Dodig, Vinko Michael, Likic, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624513/ https://www.ncbi.nlm.nih.gov/pubmed/36341992 http://dx.doi.org/10.1016/j.jinf.2022.10.030 |
Ejemplares similares
-
A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference
por: Marcec, Robert, et al.
Publicado: (2022) -
Are E-values too optimistic or too pessimistic? Both and neither!
por: Sjölander, Arvid, et al.
Publicado: (2022) -
Regdanvimab improves disease mortality and morbidity in
patients with COVID-19: A meta-analysis
por: Yang, Mingyang, et al.
Publicado: (2022) -
New life expectancy forecasts are too optimistic
por: Le Bourg, Eric
Publicado: (2021) -
COVID-19 related information and psychological distress: Too much or too bad?
por: Khubchandani, Jagdish, et al.
Publicado: (2021)